Glioblastoma Clinical Trials (April 2026): 272 Recruiting Interventional Studies
Last updated: April 24, 2026
Current Clinical Trial Landscape
Active research areas in 2026:
- CAR-T cell therapy targeting EGFRvIII, IL13Rα2, HER2, GD2, DLL3 (19 recruiting trials)
- Checkpoint immunotherapy combinations — pembrolizumab, nivolumab, retifanlimab (30 trials)
- Tumor vaccines — dendritic cell, neoantigen, peptide, and RNA-lipid particle vaccines (12 trials)
- Tumor treating fields (TTFields/Optune) combinations with immunotherapy (10 trials)
- Adaptive platform trials — GBM AGILE, INSIGhT — testing multiple agents simultaneously
Standard of care: Maximal safe resection → concurrent radiation + temozolomide → adjuvant temozolomide (Stupp protocol). Tumor treating fields (Optune) added for newly diagnosed GBM. MGMT promoter methylation predicts temozolomide benefit. For MGMT-unmethylated tumors, clinical trials are especially important as TMZ benefit is limited.
Key Biomarkers for Trial Eligibility
Most GBM trials require specific biomarker information. Knowing your status helps match you to the right trial:
- IDH status — IDH-wildtype (most common, ~90%) vs IDH-mutant. IDH-mutant gliomas are now classified separately (astrocytoma) and have different trial options including IDH inhibitors (vorasidenib).
- MGMT methylation — Methylated (~40%) vs unmethylated (~60%). Unmethylated patients benefit less from temozolomide and are prioritized for novel approaches. Several trials specifically target MGMT-unmethylated GBM.
- EGFRvIII — Present in ~25-30% of GBM. Target for CAR-T therapies and vaccine approaches.
- Newly diagnosed vs recurrent — Different trial options at each stage. Recurrent GBM has more CAR-T and immunotherapy combination trials.
Recruiting Trials by Treatment Setting
Newly Diagnosed GBM — Added to Standard Chemoradiation
Trials adding novel agents to the Stupp protocol (surgery + RT/TMZ). Several Phase 3 trials are open:
- Immunotherapy + chemoradiation:
- NCT06556563 - EF-41/KEYNOTE D58: TTFields + TMZ + pembrolizumab vs TTFields + TMZ (Phase 3)
- NCT06991101 - Ruxolitinib (JAK1/2 inhibitor) + RT/TMZ vs RT/TMZ alone (Phase 2, randomized)
- NCT05664464 - Gabapentin (glutamate inhibitor) added to standard chemoradiation (Phase 1b/2)
- Vaccine therapies:
- NCT05100641 - AV-GBM-1 dendritic cell vaccine as adjunct to RT/TMZ (Phase 3)
- NCT07347210 - UCPVax vaccine ± pembrolizumab for MGMT-unmethylated GBM (Phase 2)
- NCT06805305 - DOC1021 dendritic cell immunotherapy (Phase 2)
- Radiation innovations:
- NCT07452458 - Pulsed radiation therapy vs standard radiation for MGMT-unmethylated GBM (Phase 3)
- NCT07459101 - MR-Linac guided adaptive radiotherapy (Phase 2/3)
- NCT05450744 - IPAX-2: 131I-TLX-101 targeted radiotherapy (Phase 3)
- Temozolomide modifications:
- NCT06419946 - Lomustine + TMZ/RT for MGMT-methylated GBM (Phase 3)
- NCT05052957 - hSTAR: Chemoprotection with P140K-MGMT to allow TMZ dose escalation in MGMT-unmethylated GBM (Phase 2)
- NCT03213002 - CAPTEM: Capecitabine + temozolomide combination
- CAR-T for newly diagnosed:
- NCT06972096 - CART-EGFR-IL13Rα2 dual-target after initial radiotherapy
- Platform / adaptive trials:
- NCT03970447 - GBM AGILE: Adaptive platform testing multiple agents simultaneously (Phase 2/3)
- NCT02977780 - INSIGhT: Biomarker-driven individualized therapy platform
Recurrent / Progressive GBM
After progression on standard chemoradiation — this is where the most novel approaches are being tested:
- CAR-T cell therapy:
- NCT07180927 - DLL3-targeted CAR-T
- NCT06814029 - IL13Rα2 CAR-T (intracranial delivery)
- NCT06186401 - Anti-EGFRvIII synNotch CAR-T (conditional activation)
- NCT07523529 - Biomarker-guided dual-target CAR-T for solid tumors including GBM (Phase 1/2)
- Immunotherapy combinations:
- NCT06160206 - Retifanlimab + bevacizumab + hypofractionated RT
- NCT05271240 - Superselective intraarterial bevacizumab infusion (Phase 3)
- Vaccine therapies:
- NCT07492316 - RNA-lipid particle vaccines for recurrent GBM (Phase 1)
- Local / surgical therapies:
- Targeted / novel agents:
Showing selected notable trials. View all 272 recruiting interventional trials on ClinicalTrials.gov.
Frequently Asked Questions
How do I find glioblastoma clinical trials I'm eligible for?
Enter your GBM details into ClinTrialFinder — including IDH status, MGMT methylation, tumor grade, and prior treatments. The AI matches you with trials based on your specific profile in minutes. No login required.
What types of glioblastoma trials are currently recruiting?
There are 272 recruiting interventional trials including CAR-T cell therapy (targeting EGFRvIII, IL13Rα2, DLL3), checkpoint immunotherapy combinations, tumor vaccines (dendritic cell, neoantigen, RNA-based), tumor treating fields (TTFields) with immunotherapy, and adaptive platform trials like GBM AGILE.
Are there trials specifically for MGMT-unmethylated GBM?
Yes — MGMT-unmethylated patients benefit less from temozolomide alone, so several trials specifically target this population. Examples include pulsed radiation therapy (NCT07452458), UCPVax vaccine + pembrolizumab (NCT07347210), and chemoprotection to allow higher TMZ doses (NCT05052957).
What is the difference between IDH-wildtype and IDH-mutant glioblastoma?
IDH-wildtype GBM (~90% of cases) is more aggressive and is what most "glioblastoma" trials target. IDH-mutant gliomas are now classified separately as astrocytoma and have different treatment options, including IDH inhibitors like vorasidenib. Knowing your IDH status is essential for finding the right trials.
Find Glioblastoma Trials Matched to Your Situation
Enter your IDH status, MGMT methylation, and treatment history to get AI-matched trial results in minutes.
Find Matching Trials
